Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVieXSWX:ABBV +2.89%67 EV-to-EBIT is 58.49 as of Jul. 19, 2026, which is 138% above its 10-year median of 24.60. GuruFocus rates XSWX:ABBV with a GF Score™ of 67/100 and a GF Value™ of CHF168.24 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, AbbVie ranks worse than 87.37% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AbbVie's Enterprise Value is CHF415,260 Mil.
AbbVie's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF7,100 Mil. Therefore, AbbVie's EV-to-EBIT for today is 58.49.
The historical rank and industry rank for AbbVie's EV-to-EBIT or its related term are showing as below:
XSWX:ABBV'
s EV-to-EBIT Range Over the Past 10 Years
Min: 12.32 Med: 24.6 Max: 106.1
Current: 57.75
During the past 13 years, the highest EV-to-EBIT of AbbVie was 106.10. The lowest was 12.32. And the median was 24.60.
XSWX:ABBV's EV-to-EBIT is ranked worse than 87.37% of 689
companies
in the Drug Manufacturers industry
Industry Median: 15.8
vs XSWX:ABBV: 57.75
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AbbVie's Enterprise Value for the quarter that ended in Mar. 2026 was CHF353,862 Mil.
AbbVie's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF7,100 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie EV-to-EBIT Related Terms
AbbVie EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AbbVie's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABBV vs MRK, JNJ, AMGN: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, AbbVie's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AbbVie's EV-to-EBIT falls into.
AbbVie's current Enterprise Value is CHF415,260 Mil.
AbbVie's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF7,100 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (XSWX:ABBV) has a EV-to-EBIT of 58.49 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AbbVie and its competitors. This is 138% above median its historical median of 24.60. Over the past decade, AbbVie's EV-to-EBIT has ranged from 12.32 to 106.10. According to the industry distribution chart, AbbVie ranks #602 out of 689 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is AbbVie's EV-to-EBIT too high?
AbbVie's current EV-to-EBIT of 58.49 is 138% above median its 10-year median of 24.60. Over the past 10 years, this metric has ranged from a low of 12.32 to a high of 106.10. The Drug Manufacturers industry median EV-to-EBIT is 15.80. AbbVie's value of 58.49 is 270.2% above this industry median. Based on the distribution chart, AbbVie ranks #602 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AbbVie has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's EV-to-EBIT compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #602 out of 689 companies for EV-to-EBIT. This places AbbVie in the lower half of its industry. The industry median EV-to-EBIT is 15.80. AbbVie's value of 58.49 is 270.2% above this benchmark. Historically, AbbVie's own EV-to-EBIT has ranged from 12.32 to 106.10 over the past decade. While the company's 10-year median is 24.60 vs. the industry median of 15.80, AbbVie has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.80, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current EV-to-EBIT of 58.49 is 270.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current EV-to-EBIT is 58.49, which is 138% above median its own 10-year median of 24.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF168.24, compared to a current price of CHF208.35 — trading 23.8% above its estimated fair value. The current EV-to-EBIT is 58.49, which is 138% above median its 10-year median of 24.60 and 270.2% above the Drug Manufacturers industry median of 15.80. AbbVie's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current EV-to-EBIT is 58.49 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (XSWX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of CHF208.35 is trading 23.8% above its estimated GF Value™ of CHF168.24.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for XSWX:ABBV:
EV-to-EBIT: 58.49 (138% above median its 10-year median of 24.60)
GF Value™: CHF168.24 vs. price of CHF208.35 (23.8% above fair value)
Industry Position: 270.2% above the Drug Manufacturers median (#602 of 689)
No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
67GF Score
Get the complete analysis for XSWX:ABBV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABBV has been successfully added to your 
